(Q45972237)

English

Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin. (English)

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

Mycobacterium tuberculosis

0 references

Gilles Vergnaud

3

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

author name string

Yolande Hauck

1

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

Michel Fabre

2

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

Charles Soler

4

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

Christine Pourcel

5

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

language of work or name

0 references

publication date

11 June 2009

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

number of pages

4

1 reference

based on heuristic

inferred from page(s)

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

64

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

2

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

259-262

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

Dense-core and diffuse Abeta plaques in TgCRND8 mice studied with synchrotron FTIR microspectroscopy.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Amyloid, the presenilins and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

BACE1: the beta-secretase enzyme in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

ADAMs family members as amyloid precursor protein alpha-secretases

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Reconstitution of gamma-secretase activity

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

The amyloid precursor protein of Alzheimer's disease is found on the surface of static but not activity motile portions of neurites.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Amyloid precursor protein promotes post-developmental neurite arborization in the Drosophila brain

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Degeneration in vitro of post-mitotic neurons overexpressing the Alzheimer amyloid protein precursor.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Inflammatory markers and cognition in well-functioning African-American and white elders

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Inflammatory proteins in plasma and the risk of dementia: the rotterdam study

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Serum inflammatory proteins and cognitive decline in older persons.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Activation of microglial cells by beta-amyloid protein and interferon-gamma.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Cytokines in neuroinflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Gp130 and the interleukin-6 family of cytokines

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Microglia and neurodegeneration

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Microglia as neuroprotective, immunocompetent cells of the CNS.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Oxidative stress signalling in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Abnormalities of mitochondrial enzymes in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Peripheral markers of oxidative stress in probable Alzheimer patients.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

In vitro effect of homocysteine on some parameters of oxidative stress in rat hippocampus

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Oxidative damage is the earliest event in Alzheimer disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Rapid induction of Alzheimer A beta amyloid formation by zinc.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Fatty acids, lipid metabolism and Alzheimer pathology.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Proline-rich polypeptides in Alzheimer's disease and neurodegenerative disorders -- therapeutic potential or a mirage?

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Clinical observations with AN-1792 using TAPIR analyses

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

In vitro BACE-1 inhibitory phenolic components from the seeds of Psoralea corylifolia

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Epigallocatechin-3-gallate and curcumin suppress amyloid beta-induced beta-site APP cleaving enzyme-1 upregulation

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Long-term efficacy and safety of celecoxib in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Randomized pilot study of nimesulide treatment in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Ginkgo biloba for prevention of dementia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Statins and the risk of dementia

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Drug Development Based on the Metals Hypothesis of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.2217%2F14750708.6.2.259

21 January 2018

Identifiers

10.2217/14750708.6.2.259

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19520715

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45972237&oldid=1774793297"